Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 585 participants.

Also called NCT01697592

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 585 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01697592
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01697592. Randomized; triple masking; primary purpose treatment. Start 2012-10-24 (actual); primary completion 2014-05-08 (actual). Results posted on 2015-10-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Matching placebo to omarigliptin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01697592
Content hash
06f2810b2bdecfa04f1c23e4f47470aeb4cbcd88c0deb621b1eb41c9c40b825f